Table 1.
Measurement of the Concentration of Urinary PGE2, Urinary PGE-M, and Plasma PGE-M in the Affected Individuals, the Heterozygous Carriers, and the Unaffected Controls
| Urinary PGE2 (ng/mmol creatinine) | Urinary PGE-M (ng/mmol creatinine) | Plasma PGE-M (pg/ml) | |
|---|---|---|---|
| Affected individuals (n = 3) | 439.3 ± 234.9 | 200.0 ± 123.1 | 46.9 ± 14.4 |
| Heterozygous carriers (n = 10) | 30.0 ±20.1 | 18.9 ± 6.5 | 18.2 ± 10.5 |
| Unaffected controls (n = 5) | 26.8 ± 7.5 | 30.9 ± 16.9 | 20.2 ± 7.7 |
| p value | 0.003 | 0.000 | 0.044 |
Three separate early-morning urine samples were measured in the individuals with homozygous or compound heterozygous SLCO2A1 mutations and the unaffected controls. The standard deviations represent the intra-assay variation of the three assays with different sample dilutions.